ערך בספרים למניה: Trinity Biotech (TRIB)

Trinity Biotech plc develops diagnostics for critical pathologies, leveraging FDA certifications. The fair book value of the share visualizes this foundation, where the value of -111.19 shows the latest figure. Management is currently restructuring the business to focus on rapid tests and diabetes. Meanwhile, ultimate success depends on the implementation of test systems and the effective reduction of the company's debt obligations.

To build a defensive portfolio, I utilize book value per share, calculated as the difference between a company's total assets and liabilities divided by the number of shares outstanding. For Trinity Biotech plc (TRIB), given its global authority in medical diagnostics, this metric confirms the business's tangible stability, which is clearly illustrated by the book value per share visualization.